Abstract
Background
The varicella zoster virus (VZV) can cause two infections: chickenpox or herpes zoster (HZ). Whereas chickenpox infections are normally mild but common among children, HZ infections are common among elderly people and can give rise to post-herpetic neuralgia (PHN), a severe and painful complication.
Objectives
This review aimed to summarize the literature available on the cost effectiveness of HZ vaccination and to summarize key issues for decision makers to consider when deciding on the reimbursement of HZ vaccination.
Methods
We conducted a literature search of the databases PubMed and EMBASE using EndNote X4 from Thomson Reuters. The following combinations of keywords were used: ‘herpes zoster vaccine’ AND ‘cost(-)effectiveness’ or AND ‘economic evaluation’, ‘herpes zoster vaccination’ AND ‘cost(-)effectiveness’ or AND ‘economic evaluation’, ‘varicella zoster vaccine’ AND ‘cost(-)effectiveness’ or AND ‘economic evaluation’, and ‘varicella zoster vaccination’ AND ‘cost(-)effectiveness’ or AND ‘economic evaluation’.
Results
A total of 11 studies were identified and included. Cost-effectiveness analyses of varicella zoster vaccination were excluded. The quality of the included studies ranged from ‘moderate’ to ‘moderate to good’ according to the British Medical Journal guidelines of Drummond and Jefferson and the Quality of Health Economic Studies (QHES) score of Ofman et al. Most studies evaluated the cost effectiveness of universal HZ vaccination in adults aged 50 years or 60 years and older. Data sources and model assumptions regarding epidemiology, utility estimates and costs varied between studies. All studies calculated costs per QALY, which allows comparing costs of interventions in different diseases. The costs per QALY gained and the incremental cost-effectiveness ratio (ICER) differed between studies depending on the age at vaccination, duration of vaccine efficacy, cost of vaccine course and economic perspective. All but one of the studies concluded that most vaccination scenarios are cost effective and the vaccination of specific subgroups such as the older age group is most cost effective.
Conclusions
Model input parameters such as age at vaccination, vaccine costs, HZ incidence, PHN length and duration of vaccine efficacy had a great impact on the estimated cost effectiveness of HZ vaccination. To compare the results of different cost-effectiveness studies of HZ vaccination, uniform methods should be used and the most important input parameters used for the different models should be critically assessed.
Similar content being viewed by others
References
Bennett GJ, Watson CPN. Herpes zoster and post-herpetic neuralgia: past, present, and future. Pain Res Manage. 2009;14(4):275–82.
Wilson JF. Herpes zoster. Ann Intern Med. 2011;154(5):3–15.
Benbernou A, Drolet M, Levin MJ, et al. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain. 2011;15(10):1100–6.
Boivin G, Jovey R, Elliott CT, et al. Management and prevention of herpes zoster: a Canadian perspective. Can J Infect Dis Med Microbiol. 2010;21(1):45–52.
Drolet M, Brisson M, Levin MF, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656–66.
Chiappe SG, Sarazin M, Turbelin C, et al. Herpes zoster: burden of disease in France. Vaccine. 2010;28(50):7933–8.
Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48(Suppl. 1):2–7.
Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.
Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.
Hurley LP, Harpaz R, Daley MF, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis. 2008;197(Suppl. 2):216–23.
Lu P, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):1–6.
Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160–6.
Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39(6):537–44.
Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67(2–3):241–51.
Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23(6):490–6.
Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731–6.
Mick G, Gallais JL, Simon F, et al. Burden of herpes zoster and post-herpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over [in French]. Rev Epidemiol Sante Publique. 2010;58(6):393–401.
Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics. 2003;21(1):13–38.
Centers for Disease Control and Prevention. Childhood immunization schedule, 2011. Atlanta: CDC; 2011. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6005a6.htm. Accessed 1 Sept 2011.
Centers for Disease Control and Prevention. Adult immunization schedule, 2011. Atlanta: CDC. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6004a10.htm. Accessed 1 Sept 2011.
Sanford M, Keating GM. Zoster vaccine (Zostavax®): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159–76.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.
Levin MJ, Gershon AA, Dworkin RH, et al. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010;48(Suppl. 1):14–9.
Oxman MN, Levin MJ, et al. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008;197(Suppl. 2):228–36.
Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275–83.
Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61.
Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23–24):3076–90.
Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145(5):317–25.
Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326–37.
Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280–8.
Brisson M, Pellissier JM, Camden S, et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4(3):238–45.
Najafzadeh M, Marra CA, Galanis E, et al. Cost-effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27(12):991–1004.
van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67.
Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.
Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010;8:7.
van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.
van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet. 2006;367:219–24.
Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749–56.
Michel JP, Kempf W. Data collection related to the management of herpes zoster (HZ) and post-herpetic neuralgia (PHN) and demographic parameters in Switzerland 2007 [unpublished].
Wasem J, Lang K, Papageorgiou M, et al. Health economic evaluation of a new vaccine for the prevention of herpes zoster and post-herpetic neuralgia in adults a German analysis [abstract no. PIH22]. Value Health. 2009;12(7):A294.
Ollendorf PA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. Med Care. 2010;48(6 Suppl.):145S–52S.
Acknowledgments
The authors thank Xavier Bresse and Florence Baron-Papillon for the critical review of the manuscript and for providing constructive comments. This review was supported by an unrestricted educational grant from Sanofi Pasteur MSD. Sanofi Pasteur MSD is the provider of the HZ vaccine. The authors have no further conflict of interests to declare that are directly relevant to the contents of this article.
Author contributions
TDS designed and supervised the review. TDS obtained the funding. TDS and AMP analysed and interpreted the data. AMP drafted the manuscript. Both authors have read and approved the final manuscript and are fully responsible for the content of this article.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Szucs, T.D., Pfeil, A.M. A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination. PharmacoEconomics 31, 125–136 (2013). https://doi.org/10.1007/s40273-012-0020-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-012-0020-7